Novo Nordisk updates DKK 15bn share buyback
Novo Nordisk is updating investors on its ongoing share repurchase programme.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Novo Nordisk is updating investors on its ongoing share repurchase programme. The company plans to buy back B shares for up to DKK 15 billion over a 12‑month period starting 4 February 2026, including up to DKK 3.8 billion between 4 February and 4 May 2026.
As of 13 February 2026, Novo Nordisk has repurchased 1,750,000 B shares at an average price of DKK 305.03, for a total of DKK 533,796,640. The company now holds 19,139,799 B shares as treasury shares, equal to 0.4% of its 4,465,000,000 total A and B shares.
Insights
Novo Nordisk is executing a large, structured buyback, modestly tightening its share base.
Novo Nordisk outlines a substantial B-share repurchase framework of up to DKK 15 billion over 12 months, with a dedicated DKK 3.8 billion tranche running through early May 2026. This signals an ongoing commitment to returning capital via buybacks.
By 13 February 2026, the company had already repurchased 1,750,000 B shares for DKK 533,796,640 at an average price of DKK 305.03. Treasury holdings stand at 19,139,799 B shares, or 0.4% of the 4,465,000,000 total A and B shares.
Actual impact depends on how fully the DKK 15 billion capacity is used over the 12‑month period starting 4 February 2026 and how these repurchases interact with share issuances for incentive programmes, which caused a net transfer of 143,527 B shares during 9–13 February 2026.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Over what period will Novo Nordisk’s current DKK 3.8 billion repurchase tranche run?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
February 16, 2026
________________
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
| Form 20-F ☒ | Form 40-F ☐ |
Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 16 February 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.
Under the programme initiated 4 February 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 3.8 billion in the period from 4 February 2026 to 4 May 2026.
Since the announcement 9 February 2026, the following transactions have been made:
Number of B shares |
Average purchase price |
Transaction value, DKK | |
| Accumulated, last announcement | 750,000 | 222,297,903 | |
| 9 February 2026 | 200,000 | 316.75 | 63,350,902 |
| 10 February 2026 | 200,000 | 314.24 | 62,848,248 |
| 11 February 2026 | 200,000 | 306.43 | 61,286,959 |
| 12 February 2026 | 200,000 | 308.68 | 61,736,898 |
| 13 February 2026 | 200,000 | 311.38 | 62,275,730 |
| Accumulated under the programme | 1,750,000 | 533,796,640 |
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
Transactions related to Novo Nordisk’s incentive programmes have resulted in a net transfer from Novo Nordisk of 143,527 B shares in the period from 9 February 2026 to 13 February 2026. The shares in these transactions were not part of the Safe Harbour repurchase programme.
With the transactions stated above, Novo Nordisk owns a total of 19,139,799 B shares of DKK 0.10 as treasury shares, corresponding to 0.4% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As of 13 February 2026, Novo Nordisk has since 4 February 2026 repurchased a total 1,750,000 B shares at an average share price of DKK 305.03 per B share equal to a transaction value of DKK 533,796,640.
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
| Media: | |
| Ambre James-Brown | Liz Skrbkova (US) |
| +45 3079 9289 | +1 609 917 0632 |
| globalmedia@novonordisk.com | lzsk@novonordisk.com |
| Investors: | |
| Michael Novod | Jacob Martin Wiborg Rode |
| +45 3075 6050 | +45 3075 5956 |
| nvno@novonordisk.com | jrde@novonordisk.com |
| Max Ung | Sina Meyer |
| +45 3077 6414 | +45 3079 6656 |
| mxun@novonordisk.com | azey@novonordisk.com |
| Alex Bruce | Christoffer Sho Togo Tullin |
| +45 34 44 26 13 | +45 3079 1471 |
| axeu@novonordisk.com | cftu@novonordisk.com |
| Frederik Taylor Pitter | |
| +1 609 613 0568 | |
| fptr@novonordisk.com |
Novo Nordisk A/S Investor Relations | Novo Allé 1 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
| Company announcement No 11/ 2026 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
| Date: February 16, 2026 |
NOVO NORDISK A/S
Maziar Mike Doustdar Chief Executive Officer |